ロード中...
Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. We describe the...
保存先:
| 出版年: | Intern Med |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Japanese Society of Internal Medicine
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6355418/ https://ncbi.nlm.nih.gov/pubmed/30146570 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0923-18 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|